The Assessment of Convalescent Plasma Efficacy against COVID-19.
Med (N Y)
; 1(1): 66-77, 2020 12 18.
Article
in English
| MEDLINE | ID: covidwho-988791
ABSTRACT
Antibody-based therapy for infectious diseases predates modern antibiotics and, in the absence of other therapeutic options, was deployed early in the SARS-CoV-2 pandemic through COVID-19 convalescent plasma (CCP) administration. Although most studies have demonstrated signals of efficacy for CCP, definitive assessment has proved difficult under pandemic conditions, with rapid changes in disease incidence and the knowledge base complicating the design and implementation of randomized controlled trials. Nevertheless, evidence from a variety of studies demonstrates that CCP is as safe as ordinary plasma and strongly suggests that it can reduce mortality if given early and with sufficient antibody content.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Med (N Y)
Year:
2020
Document Type:
Article
Affiliation country:
J.medj.2020.11.002
Similar
MEDLINE
...
LILACS
LIS